ChemoCentryx Inc reports results for the quarter ended in September - Earnings Summary

Churchill Capital XI

09/11/2021 22:54

* ChemoCentryx Inc  CCXI.OQ  reported a quarterly adjusted loss
of 32 cents​​ per share for the quarter ended in September. The
mean expectation of eight analysts for the quarter was for a
loss of 45 cents per share.
* Revenue rose 248.9% to $17.74 million from a year ago; 
analysts expected $13.48 million. 
* The mean earnings estimate of analysts had risen by
about 10.8% in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate 
* ChemoCentryx Inc shares had risen by 130.2% this quarter and
lost 36.4% so far this year.
* Wall Street's median 12-month price target for ChemoCentryx
Inc is $64.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 9 at 10:54 p.m.
 ​All figures in US dollars unless otherwise stated